Overview Dividends

(AMGN) Amgen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0311621009

Rheumatoid Arthritis, Psoriasis, Osteoporosis, Anemia, Oncology

EPS (Earnings per Share)

EPS CAGR: 12.40%
EPS Trend: 75.0%

Last SUE: 2.23σ
Qual. Beats: 5

Revenue

Revenue CAGR: 12.94%
Revenue Trend: 90.7%

Last SUE: 4.00σ
Qual. Beats: 2

Risk via 10d forecast
Volatility	26.3%
Value at Risk 5%th	38.1%
Relative Tail Risk	-11.88%

Reward TTM
Sharpe Ratio	0.64
Alpha	12.68

Character TTM
Hurst Exponent	0.489
Beta	0.424
Beta Downside	0.399

Drawdowns 3y
Max DD	23.81%
Mean DD	9.99%
Median DD	9.80%

Description: AMGN Amgen September 25, 2025

Amgen Inc. (NASDAQ: AMGN) is a global biopharmaceutical company that discovers, develops, manufactures, and markets human therapeutics across a broad range of disease areas, including immunology, oncology, bone health, cardiovascular, and rare diseases.

The core portfolio features blockbuster biologics such as Enbrel (rheumatoid arthritis, psoriasis), Otezla (psoriasis, Behçet’s disease), Prolia/EvENITY (osteoporosis), XGEVA (skeletal-related events), Repatha (lipid-lowering), Nplate (immune thrombocytopenia), KYPROLIS (multiple myeloma), BLINCYTO (acute lymphoblastic leukemia), TEPEZZA (thyroid eye disease), and KRYSTEXXA (gout). Additional marketed products include Neulasta, Aimovig, LUMAKRAS, and others, extending Amgen’s reach into supportive care, migraine, and KRAS-mutated cancers.

Amgen distributes its medicines through wholesale pharmaceutical distributors, hospital and dialysis networks, and direct-to-consumer channels. The firm maintains strategic collaborations with AstraZeneca (TEZSPIRE), Novartis (Aimovig), UCB (EVENITY), Kyowa Kirin (rocatinlimab), and BeiGene (oncology), leveraging partner pipelines and shared commercialization resources.

Key recent financial metrics (FY 2023) show revenue of approximately $27 billion, a 5 % year-over-year growth driven largely by biosimilar-resistant biologics, R&D spending of $5.5 billion (≈20 % of sales), and diluted earnings per share of $6.30. The company declared a dividend of $1.30 per share, yielding roughly 3.2 % and reflecting its commitment to returning cash to shareholders.

Sector-level drivers that materially affect Amgen’s outlook include an aging U.S. population increasing demand for chronic-disease biologics, accelerating adoption of biosimilars that compress pricing on older products, and a robust pipeline of gene-editing and mRNA-based therapies that could reshape competitive dynamics in oncology and rare diseases.

For a deeper, data-rich assessment of Amgen’s valuation relative to these trends, you may find it useful to explore the analyst tools and model templates available on ValueRay.

AMGN Stock Overview

Market Cap in USD	180,967m
Sub-Industry	Biotechnology
IPO / Inception	1983-06-17
Return 12m vs S&P 500	4.77%
Analyst Rating	3.63 of 5

AMGN Dividends

Metric	Value
Dividend Yield	2.79%
Yield on Cost 5y	4.96%
Yield CAGR 5y	8.90%
Payout Consistency	100.0%
Payout Ratio	43.5%

AMGN Growth Ratios

Metric	Value
CAGR 3y	9.53%
CAGR/Max DD Calmar Ratio	0.40
CAGR/Mean DD Pain Ratio	0.95
Current Volume	2868.7k
Average Volume	2966.6k

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (7.00b TTM) > 0 and > 6% of Revenue (6% = 2.16b TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA 5.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 16.95% (prev 19.84%; Δ -2.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 13.13b > Net Income 7.00b (YES >=105%, WARN >=100%)

Net Debt (45.14b) to EBITDA (16.54b) ratio: 2.73 <= 3.0 (WARN <= 3.5)

Current Ratio 1.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (542.0m) change vs 12m ago 0.0% (target <= -2.0% for YES)

Gross Margin 66.15% (prev 60.48%; Δ 5.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 39.73% (prev 35.80%; Δ 3.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.88 (EBITDA TTM 16.54b / Interest Expense TTM 2.86b) >= 6 (WARN >= 3)

Altman Z'' 0.53

(A) 0.07 = (Total Current Assets 27.89b - Total Current Liabilities 21.79b) / Total Assets 90.14b

(B) -0.26 = Retained Earnings (Balance) -23.80b / Total Assets 90.14b

(D) 0.12 = Book Value of Equity 9.62b / Total Liabilities 80.52b

Total Rating: 0.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 82.37

1. Piotroski 8.0pt

2. FCF Yield 5.10%

3. FCF Margin 32.09%

4. Debt/Equity 5.67

5. Debt/Ebitda 2.73

6. ROIC - WACC (= 8.09)%

7. RoE 96.19%

8. Rev. Trend 90.74%

9. EPS Trend 74.95%

What is the price of AMGN shares?

As of November 26, 2025, the stock is trading at USD 341.11 with a total of 2,868,739 shares traded.
Over the past week, the price has changed by -0.13%, over one month by +17.99%, over three months by +19.09% and over the past year by +19.80%.

Is AMGN a buy, sell or hold?

Amgen has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold AMGN.

Strong Buy: 10
Buy: 5
Hold: 14
Sell: 1
Strong Sell: 2

What are the forecasts/targets for the AMGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	319.6	-6.3%
Analysts Target Price	319.6	-6.3%
ValueRay Target Price	380.3	11.5%

AMGN Fundamental Data Overview November 22, 2025

Market Cap USD = 180.97b (180.97b USD * 1.0 USD.USD)
P/E Trailing = 25.9714
P/E Forward = 15.5521
P/S = 5.0309
P/B = 19.1679
P/EG = 1.0765
Beta = 0.461
Revenue TTM = 35.96b USD
EBIT TTM = 11.11b USD
EBITDA TTM = 16.54b USD
Long Term Debt = 52.43b USD (from longTermDebt, last quarter)
Short Term Debt = 2.15b USD (from shortTermDebt, last quarter)
Debt = 54.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.14b USD (from netDebt column, last quarter)
Enterprise Value = 226.11b USD (180.97b + Debt 54.59b - CCE 9.45b)
Interest Coverage Ratio = 3.88 (Ebit TTM 11.11b / Interest Expense TTM 2.86b)
FCF Yield = 5.10% (FCF TTM 11.54b / Enterprise Value 226.11b)
FCF Margin = 32.09% (FCF TTM 11.54b / Revenue TTM 35.96b)
Net Margin = 19.48% (Net Income TTM 7.00b / Revenue TTM 35.96b)
Gross Margin = 66.15% ((Revenue TTM 35.96b - Cost of Revenue TTM 12.17b) / Revenue TTM)
Gross Margin QoQ = 67.75% (prev 67.15%)
Tobins Q-Ratio = 2.51 (Enterprise Value 226.11b / Total Assets 90.14b)
Interest Expense / Debt = 1.25% (Interest Expense 685.0m / Debt 54.59b)
Taxrate = 17.98% (705.0m / 3.92b)
NOPAT = 9.11b (EBIT 11.11b * (1 - 17.98%))
Current Ratio = 1.28 (Total Current Assets 27.89b / Total Current Liabilities 21.79b)
Debt / Equity = 5.67 (Debt 54.59b / totalStockholderEquity, last quarter 9.62b)
Debt / EBITDA = 2.73 (Net Debt 45.14b / EBITDA 16.54b)
Debt / FCF = 3.91 (Net Debt 45.14b / FCF TTM 11.54b)
Total Stockholder Equity = 7.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.77% (Net Income 7.00b / Total Assets 90.14b)
RoE = 96.19% (Net Income TTM 7.00b / Total Stockholder Equity 7.28b)
RoCE = 18.60% (EBIT 11.11b / Capital Employed (Equity 7.28b + L.T.Debt 52.43b))
RoIC = 14.16% (NOPAT 9.11b / Invested Capital 64.35b)
WACC = 6.06% (E(180.97b)/V(235.55b) * Re(7.58%) + D(54.59b)/V(235.55b) * Rd(1.25%) * (1-Tc(0.18)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 81.65 | Cagr: 0.19%
[DCF Debug] Terminal Value 79.04% ; FCFE base≈9.44b ; Y1≈9.95b ; Y5≈11.73b
Fair Price DCF = 381.6 (DCF Value 205.51b / Shares Outstanding 538.5m; 5y FCF grow 5.91% → 3.0% )
EPS Correlation: 74.95 | EPS CAGR: 12.40% | SUE: 2.23 | # QB: 5
Revenue Correlation: 90.74 | Revenue CAGR: 12.94% | SUE: 4.0 | # QB: 2

Additional Sources for AMGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle